Clinical Trials Logo

Chemotherapy clinical trials

View clinical trials related to Chemotherapy.

Filter by:

NCT ID: NCT00990821 Completed - Clinical trials for Postoperative Nausea and Vomiting

A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)

Start date: January 2005
Phase: Phase 1
Study type: Interventional

This 5-part study will evaluate the safety, tolerability, and pharmacokinetics of two formulations of MK-0517 (with and without polysorbate 80) and aprepitant in healthy adults. Parts I to IV of this study will examine different doses of MK-0517 as well as two different formulations of MK-0517 (with and without polysorbate 80). Part V of the study will compare single doses of intravenous non-PS80 MK-0517 to oral 125-mg capsule of aprepitant. The primary hypothesis for Part V of the study is that a single intravenous dose of 100-mg or 115-mg MK-0517 is area under the plasma-time curve (AUC) equivalent to that of the 125-mg oral aprepitant capsule in young healthy participants.

NCT ID: NCT00972595 Completed - Clinical trials for Chemotherapy-Induced Nausea and Vomiting

Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)

Start date: June 2004
Phase: Phase 1
Study type: Interventional

This study will assess the bioequivalence of a Merck clinical trial formulation of ondansetron compared to a non-U.S. marketed formulation of ondansetron.

NCT ID: NCT00971633 Completed - Clinical trials for Chemotherapy-Induced Nausea and Vomiting

A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)

Start date: November 2003
Phase: Phase 1
Study type: Interventional

This study will assess the bioequivalence of a Merck clinical trial formulation of ondansetron compared to a U.S. and non-U.S. marketed formulation of ondansetron.

NCT ID: NCT00952341 Completed - Clinical trials for Chemotherapy-induced Nausea and Vomiting (CINV)

Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)

Start date: August 25, 2009
Phase: Phase 3
Study type: Interventional

This study will demonstrate and confirm the efficacy and safety of MK0869 for the treatment of chemotherapy-induced nausea and vomiting in Chinese patients.

NCT ID: NCT00945321 Completed - Clinical trials for Chemotherapy-Induced Nausea and Vomiting

A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)

Start date: February 2009
Phase: Phase 1
Study type: Interventional

This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.

NCT ID: NCT00876538 Completed - Clinical trials for Chemotherapy-Induced Peripheral Neuropathy

Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy

CIPN
Start date: March 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the effect of TRO19622 on peripheral neuropathy scores after 6 weeks treatment and is based on the separate assessment of pain and dysesthesia scores.

NCT ID: NCT00787566 Completed - Clinical trials for Chemotherapy-Induced Nausea and Vomiting

Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting

Start date: October 2008
Phase: Phase 2
Study type: Interventional

Brief Summary: A randomized, single administration, double-blind, parallel- group Phase 2 dose finding study to assess the efficacy, tolerability, and safety of TRG in patients with chemotherapy-induced nausea and vomiting (CINV) associated with the administration of highly emetogenic chemotherapy. Primary Objective: To select a dose for Phase 3 by assessing the efficacy, safety, and tolerability of 3 doses of TRG in patients with CINV associated with the administration of highly emetogenic chemotherapy.

NCT ID: NCT00776724 Completed - Breast Cancer Clinical Trials

Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm

TaiNAC
Start date: May 29, 2008
Phase: Phase 3
Study type: Interventional

This is a multi-center randomized phase III trial. The purpose is to evaluate and compare the pathological complete response (pCR) rates after neoadjuvant chemotherapy with tailored chemotherapeutic regimens or standard chemotherapy for stage II/III breast cancer with tumor size more than 2 cm.

NCT ID: NCT00757094 Completed - Cancer Clinical Trials

Safety and Feasibility of Fasting While Receiving Chemotherapy

Start date: September 2008
Phase: N/A
Study type: Observational

Fasting (refraining from eating and drinking) during the day is safe while receiving chemotherapy.

NCT ID: NCT00671996 Completed - Colon Cancer Clinical Trials

Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Colon Cancer Stage Dukes' C

MANFOL
Start date: June 2008
Phase: Phase 2
Study type: Interventional

The present feasibility study is designed to find out whether pre-treatment with the compound mangafodipir lowers the frequency and severity of side effects during adjuvant chemotherapy according to the FOLFOX6 regimen in patients operated upon colon cancer in stage Dukes' C.